IRIS
LIAKOULI, Vasiliki
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.335
AS - Asia 2.993
EU - Europa 2.919
SA - Sud America 287
AF - Africa 45
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 8
Totale 11.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.261
SG - Singapore 1.334
IE - Irlanda 693
CN - Cina 664
RU - Federazione Russa 529
SE - Svezia 360
TR - Turchia 321
IT - Italia 308
HK - Hong Kong 280
DE - Germania 270
BR - Brasile 254
VN - Vietnam 236
UA - Ucraina 196
GB - Regno Unito 184
FR - Francia 138
FI - Finlandia 89
CA - Canada 50
NL - Olanda 50
IN - India 44
BE - Belgio 35
JP - Giappone 28
ZA - Sudafrica 21
BD - Bangladesh 16
PL - Polonia 16
MX - Messico 15
ES - Italia 11
ID - Indonesia 11
CZ - Repubblica Ceca 8
AR - Argentina 7
IQ - Iraq 7
SA - Arabia Saudita 7
AU - Australia 6
EC - Ecuador 6
EU - Europa 6
VE - Venezuela 6
CO - Colombia 5
LT - Lituania 5
MA - Marocco 5
NZ - Nuova Zelanda 5
TN - Tunisia 5
UZ - Uzbekistan 5
JM - Giamaica 4
JO - Giordania 4
LB - Libano 4
MY - Malesia 4
PK - Pakistan 4
PT - Portogallo 4
AT - Austria 3
DZ - Algeria 3
EG - Egitto 3
IR - Iran 3
KZ - Kazakistan 3
AL - Albania 2
BO - Bolivia 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
KE - Kenya 2
KR - Corea 2
LU - Lussemburgo 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CL - Cile 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
RO - Romania 1
Totale 11.598
Salva come PNG Salva come JPEG
Città #
Jacksonville 775
Singapore 735
Chandler 723
Dublin 693
San Jose 516
Ashburn 308
Dallas 294
Hong Kong 275
Santa Clara 247
Boardman 230
Izmir 201
The Dalles 151
Council Bluffs 150
New York 138
Ann Arbor 135
Nanjing 121
Beijing 111
Moscow 103
Lawrence 101
Princeton 101
Wilmington 101
San Mateo 93
Ho Chi Minh City 79
L'aquila 72
Los Angeles 57
Woodbridge 51
Dearborn 49
Lauterbourg 47
Milan 46
Hanoi 43
Nanchang 43
Brussels 35
Munich 33
Amsterdam 32
Shenyang 30
Seattle 28
Tokyo 28
Mountain View 27
Hefei 26
São Paulo 26
Verona 26
Helsinki 25
Kunming 25
Shanghai 24
Jiaxing 23
Hebei 22
Dong Ket 20
Des Moines 19
Frankfurt am Main 19
Rome 19
Changsha 18
Columbus 16
Orem 16
Johannesburg 15
Phoenix 15
Tianjin 15
L’Aquila 14
Montreal 14
Warsaw 14
Jinan 13
Chicago 12
San Francisco 12
Houston 11
Zhengzhou 11
Manchester 10
Atlanta 9
Chennai 9
Da Nang 9
Haiphong 9
London 9
Ningbo 9
Philadelphia 9
Pune 9
Rio de Janeiro 9
Stockholm 9
Denver 8
Grafing 8
Guangzhou 8
Toronto 8
Biên Hòa 7
Falkenstein 7
Hangzhou 7
Mumbai 7
Norwalk 7
Nuremberg 7
Pescara 7
Ankara 6
Bremen 6
Brno 6
Jakarta 6
Poplar 6
Salerno 6
Belo Horizonte 5
Brooklyn 5
Lanzhou 5
Tashkent 5
Vancouver 5
Amman 4
Bắc Ninh 4
Changchun 4
Totale 7.726
Salva come PNG Salva come JPEG
Nome #
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 203
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 159
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 159
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 158
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 157
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 155
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 154
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 153
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 151
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 150
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 148
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 143
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 138
Cardiovascular disease in primary sjögren’s syndrome 136
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 136
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 135
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 133
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 132
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 130
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 130
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 128
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 128
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 127
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 126
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 125
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 125
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 125
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 124
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 123
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 122
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 121
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 120
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 120
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 120
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 119
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 119
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 118
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. 118
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 117
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 117
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 117
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 117
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 116
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 115
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 114
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 114
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 114
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 114
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 113
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 111
Interstitial lung disease in systemic sclerosis: current and future treatment. 111
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 109
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 109
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 109
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 108
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 108
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 108
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 107
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 107
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 107
The Vessels Contribute to Fibrosis in Systemic Sclerosis 106
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 106
Cellular players in angiogenesis during the course of systemic sclerosis. 103
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 102
IMPAIREMENT OF ENDOTHELIAL DIFFERENTIATION FROM MESENCHYMAL STEM CELLS (MSC) IN SYSTEMIC SCLEROSIS (SSC): A NEW TOOL IN PATHOGENETIC MECHANISM 102
Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor 102
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosis 100
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 100
Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications 99
Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. 99
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 99
FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis 99
Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28-. T cells in RA patients and correlation with atherosclerotic damage 99
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). 99
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 98
Methotrexate: an old new drug in autoimmune disease. 97
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis: pathogenetic implication. 97
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 97
SDF-1 expression in the skin of SSc patients. 96
Pathogenesis of the endothelial damage and related factors. 95
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 95
Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 93
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. 93
Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? 92
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 91
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 91
Tocilizumab for the treatment of adult-onset Still's disease: Results from a case series 91
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC). 90
THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVATIONAL, GIRRCS STUDY 90
THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers 90
THE IL-33/ST2 PATHWAY IN SYSTEMIC SCLEROSIS 87
Mesenchymal stem cells transplantation in Systemic Sclerosis: comment on the article by ATJ Maria et al 87
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 86
ASSOCIATION OF FAS-G670A GENE POLYMORPHISM WITH SYSTEMIC SCLEROSIS 86
Modificazioni della nitrossido-sintasi neuronale (nNOS) nella cute dei pazienti con sclerosi sistemica (SSc). 82
Angiogenic cytokines and growth factors in systemic sclerosis. 82
Endothelial Progenitor Cells (EPC) characterization in systemic sclerosis (SSc) patients 80
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 80
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION. 80
Potential of stem cells in the treatment of rheumatic disease 79
Totale 11.370
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202160 0 0 0 0 0 0 0 0 0 0 0 60
2021/2022637 42 36 162 53 13 10 9 27 44 35 47 159
2022/20232.035 153 127 32 238 160 215 4 118 882 15 63 28
2023/2024484 71 35 28 51 50 158 10 25 1 22 9 24
2024/20251.974 39 38 187 62 339 154 224 149 432 82 142 126
2025/20263.591 235 346 144 428 405 275 648 136 310 390 240 34
Totale 11.751